# Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer

> **NCT05250336** · — · UNKNOWN · sponsor: **Sanjay Gandhi Postgraduate Institute of Medical Sciences** · enrollment: 1000 (estimated)

## Conditions studied

- Breast Cancer
- Tumor Infiltrating Lymphocytes
- Programmed Cell Death Ligand 1

## Interventions

- **OTHER:** Observational Study

## Key facts

- **NCT ID:** NCT05250336
- **Lead sponsor:** Sanjay Gandhi Postgraduate Institute of Medical Sciences
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-19
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250336, "Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05250336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*